The protein kinase C (PKC) family of highly related protein kinases are implicated in several diseases and have been a major focus of drug discovery efforts. However, no single drug specifically targeting a PKC isozyme has yet received approval. Here, Mochly-Rosen and colleagues review the efforts, challenges and opportunities in developing PKC modulators.
- Daria Mochly-Rosen
- Kanad Das
- Kevin V. Grimes